Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

38.80 -0.27 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Looking Into Legend Biotech's Recent Short Interest
 
Via Benzinga
A Glimpse Into The Expert Outlook On Legend Biotech Through 6 Analysts
 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Is Legend Biotech Gaining or Losing Market Support?
 
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
What Does the Market Think About Legend Biotech?
 
Via Benzinga
Is Legend Biotech Gaining or Losing Market Support?
 
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
5 Analysts Have This To Say About Legend Biotech
 
Via Benzinga
Where Legend Biotech Stands With Analysts
 
Via Benzinga
Breaking Down Legend Biotech: 9 Analysts Share Their Views
 
Via Benzinga
(LEGN) - Analyzing Legend Biotech's Short Interest
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
What Does the Market Think About Legend Biotech?
 
Via Benzinga
Demystifying Legend Biotech: Insights From 5 Analyst Reviews
 
Via Benzinga
Earnings Scheduled For March 11, 2025
 
Via Benzinga
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
9 Analysts Have This To Say About Legend Biotech
 
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Where Legend Biotech Stands With Analysts
 
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
 
Via Benzinga
Looking Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
 
Via Benzinga
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.